Expert Perspectives in Medicine

01/04/2022

NEW in : Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD, discusses the importance of multidisciplinary care for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, referencing data from a recent liver conference.
https://www.expertperspectives.com/Conference%20Reporter/Liver%20Fibrosis/multidisciplinary-care-for-nonalcoholic-fatty-liver-disease?utm_source=Facebook&utm_medium=Organic&utm_campaign=CR_LiverFibrosis&utm_content=Kowdley

Given the prevalence and clinical significance of nonalcoholic fatty liver disease (NAFLD), there is a growing call for multidisciplinary care. Opportunities for improving the identification of patients at risk for significant liver disease were highlighted in several presentations at The Liver Meet...

12/31/2021

Dr Julie Kanter provides clinical insights on managing common treatment-related adverse events in patients with sickle cell disease.
https://expertperspectives.com/Hematology/Sickle%20Cell%20Disease/managing-common-treatment-related-adverse-events-in-patients-with-sickle-cell-di?utm_source=Facebook&utm_medium=Organic&utm_campaign=Sickle_cell&utm_content=Kanter

12/27/2021

Anita Kumar, MD, Daniel O. Persky, MD, and Julie M. Vose, MD, MBA, provide information on the emerging role of chimeric antigen receptor T-cell therapy in patients with relapsed mantle cell lymphoma.
https://expertperspectives.com/Oncology/Mantle%20Cell%20Lymphoma/chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-mantle-cell-lym?utm_source=Facebook&utm_medium=Organic&utm_campaign=MCL&utm_content=Kumar_Persky_Vose

12/26/2021

NEW in : Daniel J. DeAngelo, MD, PhD, reviews emerging data from focusing on new frontiers and research needs in chronic myeloid leukemia.
https://www.expertperspectives.com/Conference%20Reporter/CML/important-frontiers-in-chronic-myeloid-leukemia-research?utm_source=Facebook&utm_medium=Organic&utm_campaign=CR_CML&utm_content=DeAngelo

At the 63rd ASH Annual Meeting and Exposition, several presentations on chronic-phase chronic myeloid leukemia (CP-CML) provided data that may add to the available knowledge base for clinical decision making. Reports of interest included findings with second-generation tyrosine kinase inhibitor (TKI...

12/26/2021

Joel M. Gelfand, MD, MSCE, comments on obesity and metabolic health in the context of psoriasis.
https://expertperspectives.com/Dermatology/Plaque%20Psoriasis/obesity-and-metabolic-health-in-patients-with-psoriasis?utm_source=Facebook&utm_medium=Organic&utm_campaign=PPSOR&utm_content=Gelfand

12/25/2021

Stella T. Chou, MD, reviews the important aspects of imaging in the care of patients with sickle cell disease.
https://expertperspectives.com/Hematology/Sickle%20Cell%20Disease/advanced-and-conventional-imaging-in-sickle-cell-disease?utm_source=Facebook&utm_medium=Organic&utm_campaign=Sickle_cell&utm_content=Chou

12/25/2021

Jeffrey Crawford, MD, says “It is important for patients to remember that targeted therapy does not mean nontoxic therapy .”
https://expertperspectives.com/Oncology/Non-Small%20Cell%20Lung%20Cancer/precision-therapies-for-non-small-cell-lung-cancer-side-effects-and-patient-educ?utm_source=Facebook&utm_medium=Organic&utm_campaign=NSCLC&utm_content=Crawford

12/24/2021

Dr Matthew J. Matasar, MD, distinguishes between bridging therapy and debulking therapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma.
https://www.expertperspectives.com/Oncology/R%20R%20DLBCL/bridging-therapy-vs-debulking-therapy-in-relapsed-refractory-diffuse-large-b-cel?utm_source=Facebook&utm_medium=Organic&utm_campaign=RR_DLBCL&utm_content=Matasar

12/24/2021

NEW in : Ashwani K. Singal, MD, MS, AGAF, FACG, FAASLD, discusses research presented at a recent liver disease meeting on the gut-liver axis and the role of the microbiome in liver disease.
https://www.expertperspectives.com/Conference%20Reporter/Liver%20Fibrosis/the-gut-liver-axis-and-the-microbiome-in-liver-inflammation-and-fibrosis?utm_source=Facebook&utm_medium=Organic&utm_campaign=CR_LiverFibrosis&utm_content=Singal

12/20/2021

Dr Stella T. Chou discusses factors that may impact hydroxyurea utilization and adherence in patients with sickle cell disease.
https://expertperspectives.com/Hematology/Sickle%20Cell%20Disease/hydroxyurea-for-sickle-cell-disease-utilization-and-adherence-patterns?utm_source=Facebook&utm_medium=Organic&utm_campaign=Sickle_cell&utm_content=Chou

12/19/2021

Psoriasis experts weigh in on defining treatment success. Commentary from Steven R. Feldman, MD, PhD, Joel M. Gelfand, MD, MSCE, and Alice B. Gottlieb, MD, PhD.
https://expertperspectives.com/Dermatology/Plaque%20Psoriasis/defining-success-in-psoriasis-care-treatment-expectations-and-clinical-goals?utm_source=Facebook&utm_medium=Organic&utm_campaign=PPSOR&utm_content=Feldman_Gelfand_Gottlieb

12/19/2021

William G. Wierda, MD, PhD, remarks, “. . . allo-transplant has become more of a last resort in recent years for a couple of reasons. . . .”
https://expertperspectives.com/Oncology/CLL/the-role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-high-risk-chro?utm_source=Facebook&utm_medium=Organic&utm_campaign=CLL&utm_content=Wierda